Roche’s Tecentriq Shows Survival In Triple-Negative Breast Cancer, For Some

Treatment with Tecentriq helped some patients with aggressive metastatic triple-negative breast cancer to live significantly longer, those that responded to treatment, according to data presented at AACR.